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Summary 
Nonpancreatic secretory phospholipase A2 (sPLA=) dis- 
plays proinflammatory properties; however, its phy- 
siological substrate is not identified. Although inactive 
toward intact cells, sPLA2 hydrolyzed phospholipids 
in membrane microvesicles shed from Ca2+-Ioaded 
erythrocytes as well as from platelets and from whole 
blood cells challenged with inflammatory stimuli, sPLA2 
was stimulated upon degradation of sphingomyelin 
(SPH) and produced lysophosphatidic acid (LPA), which 
induced platelet aggregation. Finally, lysophospho- 
lipid-containing vesicles and sPLA= were detected in 
inflammatory fluids in relative proportions identical to 
those used in vitro. We conclude that upon loss of 
phospholipid asymmetry, cell-derived microvesicles 
provide a preferential substrate for sPLA2. SPH hydro- 
lysis, which is provoked by various cytokines, regu- 
lates sPLA2 activity, and the novel lipid mediator LPA 
can be generated by this pathway. 
Introduction 
Phospholipase A2 (PLA2) is thought to play a key role in 
cell signaling by releasing arachidonic acid esterified at 
the sn-2 position of glycerophospholipids (van den Bosch, 
1980; Irvine, 1982). The best known enzymes of this group 
are secretory PLA2 (sPLA2 or type II PLA2) and cytosolic 
PLA2 (cPLA2) (reviewed by Kudo et al., 1993; Vadas et al., 
1993). Although it is generally agreed that 85 kDa cPLA2 
is the best candidate to achieve receptor-coupled arachi- 
donic acid liberation, the precise role of sPLA2 still remains 
1The first two authors contributed equally to this work. 
obscure. This 14 kDa protein is secreted by a number of 
cells in which its expression is either constitutive (e.g., 
platelets and neutrophils) or induced by inflammatory cy- 
tokines (e.g., as described in renal mesangial cells, chon- 
drocytes, vascular smooth muscle, or astrocytes), sPLA2, 
which displays proinflammatory properties, is also cur- 
rently detected in various exudates and is considerably 
increased in the plasma of patients suffering from septic 
shock, strongly suggesting a possible involvement of this 
enzyme in the inflammatory reaction. Coupled to the fact 
that its catalytic activity requires millimolar Ca 2+ concentra- 
tions, these observations have led to the concept of sPLA2 
becoming fully active upon release into the extracellular 
space. 
Among various biological membranes usceptible to in- 
teract with sPLA2, the plasma membrane of Escherichia 
coil has been the most studied, suggesting that this en- 
zyme might participate in antimicrobial defense (Wright 
et al., 1990). As for the membrane of mammalian cells, 
somewhat controversial data are available. These appar- 
ent discrepancies actually reflect the use of different cell 
models such as platelets (Mounier et al., 1993; Riendeau 
et al., 1994; Bartoli et al., 1994), which appear refractory 
to the enzyme, or various proinflammatory cells, in which 
a role of sPLA2 in arachidonic acid liberation was demon- 
strated (Hara et al., 1991; Murakami et al., 1991, 1993; 
Pernas et al., 1991; Pfeilschifter et al., 1994). However, 
opposite conclusions were also reported for macrophages 
(Barbour and Dennis, 1993; Hidi et al., 1993; Miyake et 
al., 1994). As recently discussed by Kudo et al. (1993), 
the action of sPLA2 requires a "membrane rearrangement" 
induced by tumor necrosis factor (TNF) or upon cross- 
linking of immunoglobulin E receptors. 
Phospholipid asymmetry as well as lipid packing have 
been shown to play a crucial role in modulating the activity 
of phospholipases toward biological membranes (Verkleij 
et al., 1973; Zwaal et al., 1975; Chap et al., 1977). For 
instance, pancreatic PLA2, which is unable to degrade 
phosphatidylcholine (PC) in the external eaflet of erythro- 
cyte or platelet membranes, readily hydrolyzes phosphati- 
dylserine (PS) and phosphatidylethanolamine (PE) pres- 
ent in the internal ayer, sPLA2 has a strong preference for 
anionic phospholipids and for PE and is even less efficient 
than pancreatic PLA2 at penetrating a monomolecular film 
of phospholipids (Ransac et al., 1992). Its failure to act on 
intact cells exposing choline phospholipids on their exter- 
nal surface thus appears as an obvious consequence of 
this behavior. However, the asymmetrical arrangement of 
phospholipids in the plasma membrane corresponds to a 
dynamic equilibrium susceptible to change dramatically 
under certain conditions (reviewed by Schroit and Zwaal, 
1991 ; Zwaal et al., 1992; Zachowski, 1993; Devaux, 1993). 
This has been shown particularly in erythrocytes, platelets, 
and endothelial cells in response to various agents such as 
Ca 2÷ ionophore A23187, complement membrane-attack 
complex, a combination of thrombin and collagen, or 
(z-toxin from Staphylococcus aureus. This results in the 
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Figure 1. Reverse Phase HPLC Analysis of Recombinant sPLA2 
Renatured protein (100 p_g) was loaded onto a Nucleosil C18 column 
as described in the Experimental Procedures. Elution was achieved 
using a linear gradient of acetonitrile (5%-60%) in 0.1% trifluoroacetic 
acid, which was started at the time of the injection. Protein was de- 
tected by continuous monitoring of optical density at 230 nm. The small 
peaks around 40 min correspond to unidentified impurities present in 
the buffer used for PLA2 solubilization. 
exposure of procoagulant phospholipids such as PS. In 
red cells, A23187 was shown to promote shedding of mi- 
crovesicles displaying a progressive loss of membrane 
asymmetry with surface exposure of aminophospholipids 
(Allan and Michell, 1975; Raval and Allan, 1984; Scott et 
al., 1984; Chandra et al., 1987; Comfurius et al., 1990; 
Bevers et al., 1992). Similar observations have been ex- 
tended to platelets and endothelial cells exposed to com- 
plement proteins C5b-9, which promote Ca 2+ entry into 
their target cells (Chang et al., 1993; Hamilton et al., 1990). 
This prompted us to consider the possibility that microves- 
icles formed under these conditions could provide a suit- 
able substrate for sPLA2, with Ca2÷-Ioaded erythrocytes 
appearing as the most convenient model to perform this 
study. 
In human erythrocytes, Ca 2+ ionophore also stimulates 
phosphoinositide-specific phospholipase C (PLC), which 
produces diacylglycerol, a large part of which is rapidly 
converted into phosphatidic acid (PA) (Allan and Michell, 
1975; Allan and Thomas, 1981). There is now increasing 
evidence that lysophosphatidic acid (LPA) is a novel phos- 
pholipid mediator with various biological effects, although 
the metabolic pathways responsible for its biosynthesis 
are not yet clearly established (reviewed by Moolenaar, 
1994). A second aim of this study was thus to investigate 
whether sPLA2 could hydrolyze PA present in microves- 
icles shed from Ca2÷-Ioaded erythrocytes. Our data indi- 
cate that PLA2 secreted during inflammation could be ac- 
tively involved in the generation of LPA. 
Results 
Properties of Recombinant Human sPLA= 
All the experiments were performed with a human recom- 
binant sPLA2 displaying a Met-8-~Leu mutation. This 
allows the production of the enzyme in E. coil as a fusion 
protein, which is then selectively cleaved with cyanogen 
Table 1. Hydrolysis of Microvesicle Phospholipids by Pancreatic 
and Recombinant Secretory PLA2 
sPLA2 Pancreatic PLA2 
PC 19.4 ± 1.8 (p < 0.01) 26.5 ± 3.1 (p < 0.001) 
PE 22.2 ± 2.4 (p < 0.01) 28.2 _ 6.5 (p < 0.01) 
PS 15.1 ± 5.0 (p < 0.10) 21.0 ± 1.5 (p < 0.001) 
Microvesicles were incubated for 60 min at 37°C in the absence or 
in the presence of 10 p.g/ml of recombinant human sPLA2 (four ex- 
periments) or pig pancreatic PLA2 (six experiments). Phospholipids 
were analyzed as described in the Experimental Procedures. Data 
(means ___ SEM) correspond to percentages of hydrolysis, taking into 
account he production of LPC (or LPE), or the decrease of PS. p, 
probability of significance according to Student's t test. 
bromide (CNBr), Met-8 being unique in the sequence of 
the mature enzyme. As shown by Franken et al. (1992), 
the mutation does not influence the activity of sPLA2, which 
is recovered after renaturation under oxidative conditions. 
After two successive purification steps on SP-Sephadex, 
sPLA2 appeared homogenous upon electrophoresis on 
polyacrylamide gels in the presence of sodium dodecylsul- 
fate and displayed an apparent molecular mass of 17 kDa, 
i.e., a slightly higher size than expected (14 kDa). This 
abnormal migration of both type I and type II PLA2 was 
previously reported by Aarsman et al. (1989). The most 
crucial point in the preparation of recombinant sPLA2 is 
to obtain proper refolding of the protein, which requires 
the formation of six disulfide bridges. This led us to explore 
further the physicochemical properties of the enzyme by 
reverse phase high pressure liquid chromatography (HPLC). 
As shown in Figure 1, the protein was eluted within a single 
peak at 33.09% acetonitrile, where all the PLA2 activity 
was recovered with a yield of 80%-90%. Upon reduction 
and carboxymethylation, elution occurred at 34.63% ace- 
tonitrile (data not shown), reflecting exposure of internal 
hydrophobic amino acid residues. Using didodecanoyI-PC 
as a substrate, pure sPLA2 displayed a specific activity of 
89 U/rag protein, which is comparable to the value of 115 
U/rag reported by Franken et al. (1992). Altogether, these 
data indicated that recombinant human type II PLA2 dis- 
played all the properties of the native enzyme and could 
thus be used for further experiments on membrane vesicles. 
Hydrolysis of Erythrocyte Microvesicle Phospholipids 
by Pancreatic and Secretory PLA2 
In preliminary experiments using intact erythrocytes, nei- 
ther pig pancreas PLA2 nor recombinant sPLA2 were able 
to hydrolyze phospholipids, as already shown for pancre- 
atic PLA2 (Zwaal et al., 1975). On the contrary, in microves- 
icles shed from Ca2+-Ioaded erythrocytes, both pancreatic 
PLA2 and sPLA2 hydrolyzed PC, PE, and PS to a similar 
extent (Table 1). Only PS degradation by sPLA2 was not 
significant, mainly for technical reasons. Indeed, whereas 
lysophosphatidylcholine (LPC) and lysophosphatidyletha- 
nolamine (LPE) were quantitatively recovered, lysophos- 
phatidylserine (LPS) is not extracted by current proce- 
dures. This implies the determination of PS hydrolysis by 
measuring its decrease. Since incubations were per- 
formed in the absence of lysis, these data indicated that 
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Figure 2. Effect of Sphingomyelinase on the Hydrolysis by sPLA2 of 
Phospholipids from Erythrocyte Microvesicles 
In (A), microvesicles were incubated for 60 min at 37 ° C in the presence 
of sphingomyelinase (O.1 U/ml) and various concentrations ofrecombi- 
nant human sPLA2. In (B), incubation was performed for indicated 
times in the presence of sphingomyelinase (0.1 U/ml) and sPLA2 (2 
p.g/ml). Phospholipids were analyzed as described in the Experimental 
Procedures and in Table 1. Data (means _ SEM, three different exper- 
iments) correspond to SPH (closed circles), PC (open circles), PE 
(closed squares), and PS (open squares). 
the three main classes of glycerophospholipids were pres- 
ent on the external surface of microvesicles, in agreement 
with previous reports (Raval and Allan, 1984; Scott et al., 
1984; Chandra et al., 1987; Comfurius et al., 1990). How- 
ever, both PLA2 certainly did not degrade all the glycero- 
phospholipids present in the outer layer of the membrane. 
Effect of Sphingomyelinase on the Hydrolysis 
of Erythrocyte Microvesicle Phospholipids 
by sPLA2 
In the presence of sphingomyelinase, a number of phos- 
pholipases were previously shown to degrade phospholip- 
ids in intact cells much more efficiently (Verkleij et al., 
1973; Zwaal et al., 1975; Chap et al., 1977). The same 
behavior was observed with sPLA2. Under conditions in 
which almost 800/0 of sphingomyelin (SPH) was hy- 
drolyzed, sPLA2 could degrade 50°/0 of PC, 25% of PE, 
and 12% of PS present in microvesicles (Figure 2A). Hy- 
drolysis of PC, PE, and PS could be extended to 60%, 
60%, and 30%, respectively, by increasing the incubation 
time up to 2 hr (Figure 2B). These values are quite similar 
to those previously obtained with other more penetrating 
enzymes such as Naja naja PLA2 (Scott et al., 1984), indi- 
cating that in the presence of sphingomyelinase, sPLA2 
acquires the capacity to degrade virtually all the glycero- 
phospholipids present on the external surface of microves- 
icles. 
To determine whether the effect of sphingomyelinase 
was related to the accumulation of ceramide or to the de-, 
crease of SPH, microvesicles were incubated with sPLA2 
in the presence of the membrane permeant ceramide ace- 
tyI-D-sphingosine. No significant effect could be observed 
at up to 100 p.M C2-ceramide (data not shown). 
Conversion of PA into LPA in Microvesicles 
Incubated with sPLA2 
As previously shown, accumulation of PA in erythrocyte- 
derived microvesicles can easily be followed by 32p label- 
ing (Allan et al., 1976; Allan and Thomas, 1981). Using 
this procedure, we observed a progressive hydrolysis of 
[32P]PA into [32P]LPA by sPLA2. In the absence of sphingo- 
myelinase, this did not exceed 10% (Figure 3). Here again, 
SPH degradation greatly stimulated this effect, PA hydro- 
lysis attaining 35% within 60 min in the presence of 2-10 
ilg/ml PLA2 (Figure 3). Finally, during the incubation pe- 
riod, the sum of the radioactivity associated with PA and 
LPA did not change, indicating a relative metabolic stabil- 
ity of the two compounds. 
In additional experiments, microvesicles were incubated 
with bovine serum albumin (10 mg/ml) after phospholipase 
treatment. Within 1 min, 63% of [32P]LPA was extracted 
into the supernatant and reached a maximal value of 74% 
after 30 min. Finally, to check that the accessibility of mi- 
crovesicle phospholipids to sPLA2 was not due to the use 
of a low protein medium, we repeated the phospholipase 
incubations in the presence of a physiological concentra- 
tion of albumin (40 mg/ml). Under these conditions, PA 
hydrolysis by sPLA2 alone (2 p,g/ml, 60 min) was increased 
from 6.7% _+ 1.4% to 12.7% _ 3.8% (means _+ SEM, 
three experiments). The stimulating effect of albumin was 
no longer observed when sPLA2 was used together with 
sphingomyelinase, corresponding values of PA hydrolysis 
then being 22.8% _ 2.0% and 21.1% __. 2.1%. 
Platelet Aggregation Induced by Microvesicles 
As shown in Figure 4 (trace a), LPA induced an extensive 
aggregation of human platelets, as previously described 
(Simon et al., 1982). Under the same conditions, microves- 
icles had a very slight effect (trace b), which hardly in- 
creased upon treatment with sPLA2 (trace c). However, 
microvesicles incubated for 1 hr with a combination of 
sphingomyelinase and sPLA2 induced significant platelet 
aggregation (trace d), which was dose dependent (data 
not shown). In further experiments, microvesicles were 
incubated with 10 mg/ml bovine serum albumin, and the 
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Figure 3. Conversion of [~P]PA into [~P]LPA by sPLA2 in Erythrocyte 
Microvesicles 
In (A), ~P-labeled microvesicles were incubated for 60 min at 37°C with 
various concentrations of recombinant human sPLA2, in the absence 
(open circles) or in the presence (closed circles) of sphingomyelinase 
(0.1 U/ml), In (B), the same procedure was applied except hat sPLA2 
was used at 2 p.g/ml for various incubation times as indicated. PA 
and LPA were determined for 32p radioactivity as described in the 
Experimental Procedures. Data (means _+ SEM, five and three differ- 
ent experiments in the absence and in the presence of sphingomyeli- 
nase, respectively) correspond to the percentages of radioactivity pres- 
ent in LPA, taking as 100% the sum of the radioactivity determined 
in PA and LPA, which remained constant. 
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Figure 4. Aggregation of Human Platelets by LPA and by Erythrocyte 
Microvesicles Treated with sPLA2 
Aggregation was determined under stirring (1,000 rpm) by measuring 
absorbance at 600 nm of platelet suspensions in Tyrode's buffer (300 
pl) as described previously (Simon et al., 1982). In trace (a), 1 p.I of 
a 300 pM ethanolic solution of 1-oleoyI-LPA was added at the time 
indicated by the arrow. Microvesicles (MV, 400 pl) were incubated for 
60 min without any addition in traces (b) and (f), in the presence of 
sPLA2 (2 I~g/ml) in traces (c) and (g), or in the presence of sPLA2 (2 
pg/ml) plus sphingomyelinase (Sph'ase, 0.1 U/ml) in traces (d) and 
(h). Microvesicles were then centrifuged at 12,000 x g for 10 min and 
suspended in 30 p~l of Tyrede's buffer. Aggregation was measured 
upon addition of 3 pl of this final suspension at the times indicated 
by arrows in traces (b), (c), and (d). In traces (f), (g), and (h), microves- 
icles were centrifuged at the end of the 60 rain incubation, and sus- 
pended in 30 pJ of Tyrede's buffer containing 10 mg/ml of bovine serum 
albumin. After equilibration for 10 min at room temperature, microves- 
icles were sedimented by centrifugation at 12,000 x g for 10 min, 
and 3 pl of the supernatant were added to the platelet suspension at 
the times indicated by arrows. Trace (e) shows the lack of effect of 3 
Id of the albumin solution (BSA). In trace (i), LPA (1 pM, final concentra- 
tion) was added as described for trace (a), but without stirring. Stirring 
(ST) was started as indicated, followed by a second addition of LPA 
(1 pM, final concentration). In trace (j), the same procedure was used, 
except hat the second addition (MV) corresponded to 3 I~1 of microves- 
icles treated with PI_~ and sphingomyelinase as described for trace 
(d). Data are representative of three independent experiments with 
identical results. 
resulting supernatant was added to platelet suspensions. 
Although albumin by itself had no effect (trace e), the plate- 
let-aggregating activity associated with microvesicles was 
recovered in albumin supernatants, in agreement with 
data reported above for [32P]LPA. The extent of platelet 
aggregation increased progressively using supernatants 
from control microvesicles (trace f), from sPLA2-treated 
microvesicles (trace g), and from microvesicles incubated 
with sphingomyel inase and sPLA2 (trace h). Finally, LPA 
did not induce platelet aggregation in the absence of stir- 
ring. If platelets were then stirred after 1 min, a second 
addition of LPA failed to aggregate platelets (trace i). Un- 
der these conditions, platelets remain fully responsive to 
other agonists such as platelet-activating factor, indicating 
a specific desensitization process (Simon et al., 1982; 
Sugiura et al., 1994). When microvesicles treated with 
sphingomyel inase and sPLA2 were added to piatelets pre- 
viously incubated with LPA in the absence of stirring, again 
aggregation was abolished (trace j). This strongly sug- 
gested that LPA present in microvesicles was the main 
factor involved in their platelet-aggregating activity. 
Comparison of Microvesicles Derived from 
Ca2+-Loaded Erythrocytes with Microvesicles 
Shed from Aged Red Cells 
Previous studies reported that vesicles released from 
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Figure 5. Effects of sPLA~ on 32P-Labeled 
Phospholipids Present in Vesicles Shed from 
Platelets Treated with S. aureus ~-Toxin or 
from Whole Blood Cells incubated with E. coli 
Lipopolysaccharide 
Vesicles shed from platelets treated with S. 
aureus ~z-toxin (A, B, and C) or from whole 
blood cells incubated with E. coli lipopolysac- 
charide (D, E, and F) were isolated as de- 
scribed in the Experimental Procedures. They 
were then incubated for 60 rain without any 
addition (A and D), in the presence of 2 p_g/ml 
sPLA2 (B and E), or in the presence of 2 ilg/ml 
sPLA2 plus 0.1 U/ml sphingomyelinase (C and 
F). Phospholipids were then extracted un- 
der acidic onditions, eparated by two-dimen- 
sional thin-layer chromatography, and de- 
tected by autoradiography. 
Abbreviations not used in the text: PIP, PI 
4-phosphate; PIP2, PI 4,5-bisphosphate; PPI, 
polyphosphoinositides; LPI, lysoPI; Xl and X2 
are unidentified compounds (see for instance 
Mauco et al., 1978). 
aged red cells displayed increased sensitivity to PLC 
(Shukla et al., 1978). To examine whether this more physi- 
ological model would lead to the same effects triggered 
by sPLA2, vesicles isolated from blood stored for 4 weeks 
under transfusion conditions were treated with sPLA2 and 
sphingomyelinase. However, no platelet aggregation was 
then observed. In agreement with these negative data, 
aged vesicles were found to contain much less PA (1.1% _ 
0.4%, mean _.+ SEM, four determinations) than vesicles 
obtained with calcium ionophore (5.7% _+ 0.70, eight 
determinations). Indeed, a similar difference between the 
two types of vesicles was also reported by Allan et al. 
(1976). This suggested that production of LPA by sPLA2 
might be restricted to pathological conditions, which are 
also circumstances under which sPLA2 accumulates in 
biological fluids. 
Effects of sPLA2 on Microvesicles Shed from 
Platelets or from Whole Blood Cells Treated with 
S. aureus ~z-Toxin or with E. coil Lipopolysaccharide 
To define more biological systems likely to react to sPLA2 
in a similar way as vesicles shed from Ca2÷-Ioaded erythro- 
cytes, 3zP-labeled platelets were treated with S. aureus 
s-toxin. This toxin is thought o play a major role in patho- 
logical events accompanying sepsis (Bhakdi et al., 1994). 
Phospholipids from vesicles isolated under these condi- 
tions displayed the same susceptibility to sPLA2 as red 
cell microvesicles. In the presence of sphingomyelinase, 
sPLA2 achieved a significant degradation of most labeled 
phospholipids, i.e., PC, phosphatidylinositol (PI), and PA, 
which were converted into the corresponding lysophos- 
pholipids (Figures 5A-5C). 
Very similar data (see Figures 5D-5G) were obtained 
upon incubation of whole blood cells with lipopolysaccha- 
ride, which also plays a central role in septic shock, includ- 
ing direct cellular effects (Vadas et al., 1993) and activation 
of the alternative complement pathway (Minta and Gee, 
1983). Other pathological in vitro models were also exam- 
ined, including treatment of whole blood cells with S. 
aureus s-toxin or with zymosan, and they gave almost 
identical results (data not shown). 
Isolation of Microvesicles from Inflammatory Fluids 
To hav, at least one example of similar vesicles occurring 
under in vivo pathological conditions, inflammatory fluids 
obtained from patients suffering from arthritis were exam- 
ined for the presence of vesicle material. As shown in 
Table 2, vesicles particularly rich in LPC and LPE could 
be isolated, strongly suggesting the contribution of sPLA2 
detected in supernatants. Vesicles were present at a con- 
centration of 7.4 nmol of phospholipids/ml, which is 10-fold 
lower than the concentrations used in our in vitro incuba- 
tions. However, the concentration of sPLA2 could be esti- 
mated at 1.2 i~g/ml, since pure recombinant sPLA2 dis- 
played a specific activity of 60 mU/p.g protein using the 
same assay. This indicated that the ratio sPLA2 to vesicle 
phospholipids in the inflammatory fluids was in the same 
range as that used during our in vitro experiments (10 I~g/ 
ml sPLA2 for 80-120 nmol/ml phospholipids). To verify that 
the presence of sPLA2 and vesicles reflected an inflamma- 
Table 2. PLA2 Activity and Vesicle Phospholipid Analysis in 
Inflammatory Fluids from Patients Suffering from Arthritis 
PLA2 activity 71.3 ± 29.6 mU/ml 
Total phospholipids 7.4 ± 1.8 nmol/ml 
Phospholipid composition 
LPC 11.3% -+ 2.5% 
LPE 13.5% ± 0.5% 
SPH 20.4% ± 4.9% 
PC 24.8% ± 2.3% 
PS 4.8% _ 4.8% 
PE 22.5% ± 4.6% 
Others 2.7% _+ 1.6% 
Inflammatory fluids were drawn from knees of patients suffering from 
arthritis (two rheumatoid arthritis, one Churg and Strauss syndrome). 
Vesicles were isolated and analyzed for phospholipids as described 
in the Experimental Procedures. The 200,000 x g supernatant was 
determined for PLA2 activity according to Radvanyi et al. (1989). Data 
are means ± SEM of three values. 
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tory process, 1 ml of fluid was collected from the knee 
of a patient suffering from a small arthrosis lesion on a 
meniscus. PLA2 activity was only 1 mU/ml, whereas vesi- 
cles were absent. 
Discussion 
The present investigation led to three interesting observa- 
tions, allowing us to propose a novel role for sPLA2 in 
cell signaling, particularly during inflammation. The first 
concerns the ability of the enzyme to degrade phospholip- 
ids in vesicles shed from Ca2+-Ioaded eryth rocytes. Since 
internal phospholipids uch as PE and PS were hydrolyzed 
under nonlytic conditions, this promotes the view that the 
loss of membrane phospholipid asymmetry plays a key 
role in the capacity of sPLA2 to penetrate into the external 
layer of the vesicle membrane. We thus propose that the 
"membrane rearrangement" suggested by Kudo et al. 
(1993) to allow interaction of sPLA2 with mammalian cells 
could involve the movement of phospholipids from the in- 
ternal to the external leaflet of the membrane. 
From a functional point of view, the loss of membrane 
phospholipid asymmetry has mainly been considered in 
relation to blood coagulation (Zwaal et al., 1992) and to 
recognition by monocytes/macrophages ofcells undergo- 
ing in vivo clearing (Schwartz et al., 1985; Connor et al., 
1994; Fadok et al., 1992). Our finding suggests a new 
meaning for the loss of membrane phospholipid asymme- 
try, which might regulate the accessibility of cell mem- 
branes to sPLA2. So now a main question is to know 
whether similar vesicles can be formed under physiologi- 
cal or pathological conditions allowing a possible contact 
with sPLA2. 
As a first attempt to evaluate the biological relevance 
of our experimental model, we were able to isolate from 
inflammatory fluids microvesicles displaying large amounts 
of lysophospholipids bathing in a medium containing a 
relative proportion of sPLA2 very close to that used during 
in vitro incubations. Also, in an effort to outline possible 
pathological processes responsible for microvesicle shed- 
ding, $. aureus m-toxin and lipopolysaccharide were found 
to generate from platelets and from whole blood cells, 
respectively, microvesicles displaying the same sensitivity 
to sPLA2 as that previously observed using Ca2+-Ioaded 
erythrocytes. Whereas the role of lipopolysaccharide in 
E. coli-induced septic shock is well understood, the model 
using R-toxin is particularly interesting for three reasons. 
First, S. aureus m-toxin is an example of a pore-forming 
protein promoting Ca2÷-dependent shedding of microves- 
icles and loss of membrane phospholipid asymmetry by 
a mechanism identical to that of the complement mem- 
brane-attack complex (Arvand et al., 1990; Chang et al., 
1993; Hamilton et al., 1990; Stein and Luzio, 1991). Sec- 
ond, a recent review outlined the possible role of this and 
other similar bacterial exotoxins in the pathogenesis of 
sepsis syndrome and septic shock (Bhakdi et al., 1994). 
Third, S. aureus also secretes 13-toxin, which is identical 
to sphingomyelinase C used in the present study. 
This should lend more importance to our second conclu- 
sion that the activity of sPLA2 toward membrane microves- 
icles is greatly increased upon SPH hydrolysis. Although 
such a dual effect of a- and 13-toxins would be restricted 
to infections by S. aureus, the stimulation of sPLA2 by 
sphingomyelinase might be particularly important o con- 
sider in the light of recent studies demonstrating that con- 
version of SPH into ceramide is a key signaling event 
evoked by a number of proinflammatory cytokines such 
as TNF or interleukin-1 (reviewed by Heller and KrSnke, 
1994; Hannun, 1994; Kolesnick and Golde, 1994). In the 
same manner exogenous sphingomyelinase can repro- 
duce some biological effects of proinflammatory cyto- 
kines, we thus suggest that endogenous sphingomyeli- 
nase activated in response to TNF might enable the action 
of extracellular sPLA2. 
A third important result concerns the conversion of PA 
into LPA by sPLA2. At first, this was unexpected, since 
PA is thought to be synthesized on the inner side of the 
plasma membrane (Allan and Michell, 1975; Allan and 
Thomas, 1981). The fact that hydrolysis levels as high as 
35% could be measured under nonlytic conditions shows 
unambiguously that PA itself undergoes an outward move- 
ment in the membrane of microvesicles. Thus, sPLA2 
could play a key role in the generation of LPA. It will be 
important to identify which vesicles other than those inves- 
tigated herein would display loss of membrane asymme- 
try, SPH hydrolysis, and accumulation of PA as a conse- 
quence of cell activation. Vesicles derived from cells 
treated by TNF or complement membrane-attack complex 
appear as interesting potential candidates, since both 
agents were previously shown to activate SPH hydrolysis 
and the degradation of PC by a specific PLC (Schutze et 
al., 1991; Niculescu et al., 1993). 
Finally, although PLA2-treated microvesicles promoted 
platelet aggregation, albumin was found to extract almost 
totally both LPA and platelet-aggregating activity, in agree- 
ment with previous observations (Eichholtz et al., 1993). 
This suggests that albumin is likely to be a major presenter 
of LPA during inflammatory responses. Also, despite the 
results of specific desensitization, it is not certain that all 
the platelet-aggregating activity is supported by LPA 
alone, since other lipid derivatives uch as arachidonic 
acid liberated by sPLA2 could also be involved. 
In conclusion, the use of a model system of microves- 
icles shed from Ca2+-Ioaded erythrocytes allowed us to 
propose some new concepts concerning the possible 
mechanism and role of sPLA2, which have remained ob- 
scure until now. The fact that loss of membrane phospho- 
lipid asymmetry and sphingomyelin hydrolysis regulate 
the activity of sPLA2 should not mask a complementary 
role of cofactor proteins such as phospholipase-activating 
protein or PLAP (Clark et al., 1991). Finally, although we 
have mainly focused our study on LPA, Other lysophospho- 
lipids generated by sPLA2 should be considered, since 
LPC can activate some isoforms of protein kinase C 
(Asaoka et al., 1993), whereas LPS stimulates mast cell 
degranulation (Murakami et al., 1992). 
Experimental Procedures 
Materials 
Calcium ionophore A23187, dilauroyI-PC, D-sphingosine from bovine 
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brain SPH, PLA2 from pig pancreas, sphingomyelinase and (~-toxin 
from S. aureus, lipopolysaccharide from E. coil K235, l..oleoyI-LPA, 
and bovine serum albumin, essentially fatty acid free, were obtained 
from Sigma. [a2P]o-phosphate was from Amersham. Silica gel 60 plates 
(0.25 mm thick) were obtained from Merck. N-acetyI-D-sphingosine 
(C2-ceramide) was synthesized by acetylation of o-sphingosine with 
acetic anhydride as described (Gaver and Sweeley, 1966). 
Preparation of Recombinant Human sPLA= 
This was adapted from two previous studies as follows (Pernas et al., 
1991; Franken et al., 1992). Total cDNA was prepared from human 
placenta mRNA by reverse transcriptase in the presence of poly(dT) 
primer using the Superscript kit from BRL. The cDNA coding for human 
sPLA2 was amplified by PCR using Taq DNA polymerase (Beckman) 
and a Perkin Elmer thermal cycler. Primers were synthesized by the 
solid phase phosphoramidite method on an Applied Biosystem 391 A 
automated oligonucleotide synthesizer. Upstream primer (5'-GCGGC- 
GAAI-FCATGAATI-FG G TGAATI-ICCACAGACTGATC-3') contained 
an Xbal restriction site and a Met-8~Leu mutation of the unique methi- 
onine residue present in the sequence of human sPLA2, the nucleotide 
modification being underlined in the sequence of the primer given 
above. Downstream primer (5'-AAAAGGGTCGACAGGGAAGAGGG- 
GACTCAAGT-3') included a stop codon and a Sail restriction site. With 
the exception of the Met-8-*Leu mutation, the amplified cDNA thus 
coded for the sequence covering from Asn-1 to the C-terminus of ma- 
ture human sPLA2 (Seilhammer et al., 1989; Kramer et al., 1989). The 
PCR product was purified, sequenced, and inserted into the polylinker 
of the expression plasmid pGEX-2T (Pharmacia) using Xbat and Sail 
restriction sites. The resulting fusion plasmid (pGEX-PLA2) coding for 
a fusion protein glutathione S-tranferase-sPLA2 was used to transform 
E. coil strain XL 1 Blue (Stratagene). Expression of the fusion protein 
was induced by isopropyl-I~-D-thiogalactoside, inclusion bodies iso- 
lated after cell lysis were solubilized in 50 mM Tris-HCI (pH 8.0) con- 
taining 6 M guanidine, proteins were S-sulfonated according to Thann- 
hauser and Scheraga (1985), and hydrolyzed with a 70-fold molar 
excess of CNBr in 75°/0 formic acid (v/v). After dialysis against 5 mM 
acetic acid, soluble material was freeze dried, the resulting powder 
being solubilized in 3 M guanidine. Disulfide bridges were formed upon 
dialysis against 5 mM CaCI2, 5 mM cysteine, and 0.8 M guanidine. 
Active PLA2 was recovered by dialysis against 50 mM acetate buffer 
(pH 4.5) containing 150 mM NaCI. The renatured enzyme was purified 
bytwo successive runs on an SP-Sephadex C-25 column (Pharmacia) 
and eluted by a linear NaCI gradient (0.15-2 M) in 50 mM acetate 
buffer (pH 6.0). 
Reverse Phase HPLC 
This was performed as previously described (Rugani et al., 1992) using 
a 4 x 120 mm Nucleosil C18 column equilibrated at room temperature 
with 0.1% (v/v) trifluoroacetic acid in water and developed at 1 ml/min 
with a linear gradient of acetonitrile (5%-60%) in 0.1% trifluoroacetic 
acid. in each run, 100 p.g of purified PLA2 was injected. Alternatively, 
PLA2 was previously reduced and carboxymethylated before HPLC 
analysis. This was achieved by incubating protein with 0.033 M dithio- 
threitol for 5 rain at 96°C, followed by alkylation with 0.166 M iodoace- 
tate for 30 rain at 37°C. 
Determination of PLA2 Activity 
Recombinant sPLA2 was determined for enzyme activity using dilau- 
royI-PC as a substrate (Franken et al., 1992). Incubation was per- 
formed for 15 rain at 37°C, lipids were extracted and separated by 
thin-layer chromatography, and the amount of LPC formed during the 
reaction was measured as described elsewhere (Gassama-Diagne t 
al., 1992), Alternatively, PLA2 activity was determined using a substrate 
fluorescent assay (Radvanyi et al., 1989). 
Preparation of Microvesicles Shed from 
Ca2*-Loaded Erythrocytes 
This was achieved essentially according to Allan et al. (1980). Fresh 
blood obtained from normal volunteer donors was drawn onto 0.129 
M buffered sodium citrate (1 part to 9 parts of blood, Becton Dickinson 
Vacutainer System). Red cells were isolated by centrifugation at 200 x 
g (room temperature) and washed three times by centrifugation at 
400 x g in buffer A containing 140 rnM NaCI, 2.7 mM KCI, 1 mM 
MgCI2, 5 mM glucose, 10 mM HEPES (pH 7.4). Erythrocytes were 
suspended in buffer A at 5 x 106 cells/ml, CaCI2 (1 m M, final concentra- 
tion) was then added, followed by 2 p.M A23187, and incubation was 
performed at 37°C for 45 min under magnetic stirring. Intact cells 
were eliminated by centrifugation at 1,500 x g for 15 rain, and the 
supernatant was centrifuged at 13,000 x g for 20 min, allowing it to 
obtain a microvesicle pellet. In preliminary experiments, a relationship 
was established between the hemoglobin level of the vesicles lysed 
in water and their phospholipid content. In this way, vesicle concentra- 
tion in buffer A was adjusted in order to contain 80-120 nmol of phos- 
pholipid/ml, lipid phosphorus content being determined accurately at 
the end of the various incubations performed afterward. In those exper- 
iments dealing with the production of PA and LPA, red cells were 
incubated for 1 hr in buffer A containing 15 ~.Ci/ml of [UP]o-phosphate, 
and 32P-labeled vesicles were isolated exactly as described. 
Preparation of Microvesicles from Platelets or Whole Blood 
Cells Treated with ~x-Toxin or Lipopolysaccharide 
Human blood platelets (5 x 108 cells) isolated according to Ardlie et 
al. (1970) were labeled with [32P]o-phosphate (200 pCi/ml, 1 hr, 37°C) 
and, after washing, were suspended at the same concentration in 
buffer A containing 1 mM CaCI2. After incubation for 30 rain at 37°C 
with 2 ~g/ml s-toxin, platelets were sedimented at 1,500 x g for 15 
rain, and vesicles were isolated at 13,000 x g for 15 rain. 
Heparinized human blood (15 ml) was incubated with [32P]o-phos- 
phate (500 p, Ci/ml), diluted with 35 ml RPMI, and incubated under 
sterile conditions for 19 hr at 37°C in the presence of lipopolysac- 
charide (10 p.g/ml). Cells were then discarded by centrifugation at 
1,500 × g for 30 rain, and vesicles were sedimented at 200,000 x 
g for 30 min. 
Incubation of Microvesicles with Phosphoiipases 
Suspensions of microvesicles in buffer A containing 1 mM CaCI2 were 
incubated at 37°C for various times under magnetic stirring, in the 
absence or in the presence of sphingomyelinase (0.1 U/ml), and vari- 
ous concentrations of recombinant sPLA2 or pig pancreas PLA2 (1-10 
~g/ml). At the end of the incubation, 5 mM EEDTA (final concentration) 
was added, followed by 2 vol of chloroform/methanol (1/1 by vol). In 
some experiments, the suspension was centrifuged at 12,000 × g for 
10 rain and the hemoglobin content of the supernatant was estimated 
from the absorbance at 540 nm. This indicated the absence of lysis 
during the various treatments of the microvesicles. 
Phospholipid Analysis 
Lipids were extracted according to Bligh and Dyer (1959) or by a modi- 
fied procedure including acidification with concentrated HCI (60 p.I/ml 
suspension) when LPA was analyzed (Mauco et al., 1978). After phase 
separation, the organic layer was dried under nitrogen and dissolved in 
chloroform/methanol (1/1 by vol). One aliquot was used for phosphorus 
determination (B~ttcher et al., 1961), major phospholipids present in 
the remaining extract being separated by two-dimensional thin-layer 
chromatography using chloroferm/methanol/20O/o N H3 (65/25/5, by vol) 
and chloroform/methanol/acetic a id/water (45/20/6/1) as solvents. 
The various spots were detected upon exposure to iodine vapor, 
scraped off, and determined for phosphorus content. When [~2P]PA 
and [32P]LPA were analyzed, lipids were separated by one-dimensional 
thin-layer chromatography on silica gel 60 plates impregnated with 
0.25 M oxalic acid as described (Mauco et al., 1978), using chloroform/ 
methanol/12 M HCI (87/13/0.5, by vol) as a solvent. Radioactive phos- 
pholipids were detected by auteradiography, scraped off, and deter- 
mined for 32p radioactivity by scintillation counting. 
Isolation of Microvesicles from Inflammatory Exudates 
Inflammatory fluids were obtained by direct punction into the knees 
of patients suffering from arthritis (two rheumatoid arthritis, one Churg 
and Strauss syndrome) and anticoagulated with EDTA. Cells were 
eliminated by centrifugation at 1,500 x g for 30 min; vesicles were 
pelleted at 200,000 × g for 30 min and washed once in buffer A 
before lipid extraction. The first 200,000 × g supernatant was used 
for determination of PLA2 activity. 
Miscellaneous 
Platelet aggregation was measured as previously described using sus- 
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pensions of human platelets (Simon et al., 1982). Protein was deter- 
mined according to Bradford (1976) using bovine serum albumin as 
a standard. Polyacrylamide gel electrophoresis in the presence of so- 
dium dodecyl sulfate was performed according to Laemmli (1970) us- 
ing 15% polyacrylamide. 
Acknowledgments 
Correspondence should be addressed to H. C. Thanks are due to Mr 
P. RogaUe for the synthesis of N-acetyI-D-sphingesine, to Mrs R. Y. 
Li for the gift of 32P-labeled platelets, and to Dr. P. Bonnevialle for 
providing noninflammatory fluid. We are indebted to Mrs Y. Jonqui~re 
and to Miss J. Allan Yorke for correcting the English manuscript. This 
work was supported by a grant from the Ministere de rEnseignement 
Superieur et de la Recherche. This study is devoted to the memory 
of Prof. L. L. M. van Deenen, departed in September 1994. 
Received August 24, 1994; revised January 26, 1995. 
References 
Aarsman, A. J., de Jong, J. G. N., Arnolduseen, E., Neys, F. W., van 
Wassenaar, P. D., and van den Bosch, H. (1989). Imm unoaffinity purifi- 
cation, partial sequence, and subcellular localization of rat liver phos- 
pholipase A2. J. Biol. Chem. 264, 10008-10014. 
Allan, D., and Michell, R. H. (1975). Accumulation of 1,2-diacylgiycerol 
in the plasma membrane may lead to echinocyte transformation of 
erythrocytes. Nature 258, 348-349. 
Allan, D., and Thomas, P. (1981). Ca2+-induced biochemical changes 
in human erythrocytes and their relation to microvesiculation. Bio- 
chem. J. 198, 433-440. 
Allan, D., Watts, R., and Michell, R. H. (1976). Production of 1,2- 
diacylglycerol and phosphatidate in human erythrocytes treated with 
calcium ions and ionophore A23187. Biochem. J. 156, 225-232. 
Allan, D., Thomas, P., and Limbrick, A. R. (1980). The isolation and 
characterization of 60 nm vesicles ("nanovesicles") produced during 
ionophore A23187-induced budding of human erythrocytes. Biochem. 
J. 188, 881-887. 
Ardlie, N. G., Packham, M. A., and Mustard, J. F. (1970). Adenosine 
diphosphate-induced platelet aggregation in suspensions of washed 
rabbit platelets. Br. J. Haematol. 19, 7-17. 
Arvand, M., Bhakdi, S., Dahlback, B., and Preissner, K. T. (1990). 
Staphylococcus aureus {z-toxin attack on human platelete promotes 
assembly of the prothrombinase complex. J. Biol. Chem. 265, 14377- 
14381. 
Asaoka, Y., Yoshida, K., Sasaki, Y., and Nishizuka, Y. (1993). Potential 
role of phospholipase A2 in HL-60 cell differentiation to macrophages 
induced by protein kinase C activation. Proc. Natl. Acad. Sci. USA 
90, 4917-4921. 
Barbour, S. E., and Dennis, E. A. (1993). Antisense inhibition of group 
II phospholipase A2 expression blocks the production of prostaglandin 
E2 by P388D1 cells. J. Biol. Chem. 268, 21875-21882. 
Bartoli, F., Lin, H.-K., Ghomashi, F., Gelb, M. H., Jain, M. K., and 
Apitz-Castro, R. (1994). Tight binding inhibitors of 85-kDa phospholi- 
pase A2 but not 14-kDa phospholipase A2 inhibit release of free arachi- 
donate in thrombin-stimulated human platelets. J. Biol. Chem. 269, 
15625-15630. 
Bevere, E. M., Wiedmer, T., Comfuriue, P., Shattil, S. J., Weiss, H. J., 
Zwaal, R. F. A., and Sims, P. J. (1992). Defective Ca2---induced mi- 
crovesiculation and deficient expression of procoagulant activity in 
erythrocytes from a patient with a bleeding disorder: a study of the 
red blood cells of Scott syndrome. Blood 79, 380-388. 
Bhakdi, S., Grimminger, F., Suttorp, N., Walmrath, D., and Seeger, 
W. (1994). Proteinaceous bacterial toxins and pathogenesie of sepsis 
syndrome and septic shock: the unknown connection. Med. Microbiol. 
Immunol. 183, 119-144. 
Bligh, E. G., and Dyer, W. J. (1959). A rapid method of total lipid 
extraction and purification. Can. J. Biochem. Physiol. 37, 911-918. 
BSttcher, C. J. F., van Gent, C. M., and Pries, C. (1961). A rapid and 
sensitive sub-micro phosphorus determination. Anal. Chim. Acta 24, 
203-204. 
Bradford, M. M. (1976). A rapid and sensitive method for the quantita- 
tion of microgram quantities of protein utilizing the principle of protein- 
dye binding Bradford protein assay. Anal. Biochem. 72, 248-254. 
Chandra, R., Joshi, P. C., Bajpai, V. K., and Gupta, C. M. (1987). 
Membrane phospholipid organization in calcium-loaded human eryth- 
rocytee. Biochim. Biophye. Acta 902, 253-262. 
Chang, C.-P., Zhao, J., Wiedmer, T., and Sims, P. J. (1993). Contribu- 
tion of platelet microparticle formation and granule secretion to the 
transmembrane migration of phosphatidylserine. J. Biol. Chem. 268, 
7171-7178. 
Chap, H., Zwaal, R. F. A., and van Deenen, L. L. M. (1977). Action 
of highly purified phospholipases on blood platelets: evidence for an 
asymmetric distribution of phospholipids in the surface membrane. 
Biochim. Biophys. Acta 467, 146-164. 
Clark, M. A., Ozgl3r, L. E., Conway, T. M., Dispoto, J., Crooke, S. T., 
and Bomalaski, J. S. (1991). Cloning of a phoepholipase A2-activating 
protein. Proc. Natl. Acad. Sci. USA 88, 5418-5422. 
Comfurius, P., Senden, J. M. G., TiUy, R. H. J., Schroit, A. J., Bevere, 
E. M., and Zwaal, R. F. A. (1990). Loss of membrane phospholipid 
asymmetry in platelets and red cells may be associated with calcium- 
induced shedding of plasma membrane and inhibition of aminophos- 
pholipid translocase. Biochim. Biophys. Acta 1026, 153-160. 
Connor, J., Pak, C. C., and Schroit, A. J. (1994). Exposure of phosphati- 
dylserine in the outer leaflet of human red blood cells: relationship to 
cell density, cell age, and clearance by mononuclear cells. J. Biol. 
Chem. 269, 2399-2404. 
Devaux, P. F. (1993). Lipid transmembrane asymmetry and flip-flop 
in biological membranes and in lipid bilayers. Curr. Opin. Struct. Biol. 
3, 489-494. 
Eichholtz, T., Jalink, K., Fahrenfort, I., and Moolenaar, W. H. (1993). 
The bioactive phospholipid lyeophosphatidic acid is released from acti- 
vated platelete. Biochem. J. 291,677-680. 
Fadok, V. A., Savill, J. S., Haslett, C., Bratton, D. L., Doherty, D. E., 
Campbell, P. A., and Henson, P. M. (1992). Different populations of 
macrophages use either the vitronectin receptor or the phosphatidyl- 
eerine receptor to recognize and remove apoptotic cells. J. Immunol. 
149, 4029-4035. 
Franken, P. A., van den Berg, L., Huang, J., Gunyuzlu, P., Lugtigheid, 
R. B., Verheij, H. M., and de Haas, G. H. (1992). Purification and 
characterization of a mutant human platelet phoepholipase A2 ex- 
pressed in Escherichia coil: cleavage of a fusion protein with cyanogen 
bromide. Eur. J. Biochem. 203, 89-98. 
Gassama-Diagne, A., Rogalle, P., Fauvel, J., Willson, M., Kla~b~, A., 
and Chap, H. (1992). Substrate specificity of phoepholipase B from 
guinea pig intestine: a glycerol ester lipase with broad substrate speci- 
ficity. J. Biol. Chem. 267, 13418-13424. 
Gaver, R. C., and Sweeley, C. C. (1966). Chemistry and metabolism 
of sphingolipids: 3-oxo derivatives of N-acetylephingosine and 
N-acetyldihydroephingoeine. J. Am. Chem. Soc. 88, 3643-3647. 
Hamilton, K. K., Hattori, R., Esmon, C. T., and Sims, P. J. (1990). 
Complement proteins C5b-9 induce vesiculation of the endothelial 
plasma membrane and expose catalytic surface for assembly of the 
prothrombinase nzyme complex. J. Biol. Chem. 265, 3809-3814. 
Hannun, Y. A. (1994). The sphingomyelin cycle and the second mes- 
senger function of ceramide. J. Biol. Chem. 269, 3125-3128. 
Hara, S., Kudo, I., and Inoue, K. (1991) Augmentation of prostaglandin 
E2 production by mammalian phospholipase A~ added exogenously. 
J. Biochem. 110, 163-165. 
Heller, R. A., and Kr6nke, M. (1994). Tumor necrosis factor receptor- 
mediated signaling pathways. J. Cell Biol. 126, 5-9. 
Hidi, R., Vargaftig, B. B., and Touqui, L. (1993). Increased synthesis 
and secretion of a 14-kDa phospholipase A2 by guinea pig alveolar 
macrophages: dissociation from arachidonic acid liberation and modu- 
lation by dexamethasone. J Immunol. 151, 5613-5623. 
Irvine, R. F. (1982). How is the level of free arachidonic acid controlled 
in mammalian cells? Biochem. J. 204, 3-16. 
Secretory Phosphoiipase A2 and Lysophosphatidic Acid 
927 
Kolesnick, R., and Golde, D. W. (1994). The sphingomyelin pathway 
in tumor necrosis factor and interleukin-1 signaling. Cell 77, 325-328. 
Kramer, R. M., Hession, C., Johansen, B., Hayes, G., McGray, P., 
Chow, E. P., Tizard, R., and Pepinsky, R. B. (1989). Structure and 
properties of a hu man non-pancreatic phospholipase A2. J. Biol. Chem. 
264, 5768-5775. 
Kudo, I., Murakami, M., Hara, S., and Inoue, K. (1993). Mammalian 
non-pancreatic phospholipases A2. Biochim. Biophys. Acta 1170,217- 
231. 
Laemmli, U. K. (1970). Cleavage of structural proteins during the as- 
sembly of the head group bacteriophage T4. Nature 227, 680-685. 
Mauco, G., Chap, H., Simon, M. F., and Douste-Blazy, L, (1978). Phos- 
phatidic and lysophosphatidic acid production in phospholipase C- and 
thrombin-treated platelets: possible involvement of a platelet lipase. 
Biochimie 60, 653-661. 
Minta, J. O., and Gee, A. P. (1983). Purification and quantitation of 
the components of the alternative complement pathway. Meth. Enzy- 
rnol. 93, 375-408. 
Miyake, A., Yamamoto, H., Enomori, T., and Kawashima, H. (1994). 
Exogenous group II phospholipase A2 induces prostaglandin E2 pro- 
duction in mouse peritoneal macrophages. Eur. J. Pharmacol. 253, 
155-161. 
Moolenaar, W. H. (1994). LPA: a novel lipid mediator with diverse 
biological actions. Trends Cell Biol. 4, 213-219. 
Mounier, C., Faili, A., Vargaftig, B. B., Bon, C., and Hatmi, M. (1993). 
Secretory phospholipase A2 is not required for arachidonic acid libera- 
tion during platelet activation. Eur. J. Biochem. 216, 169-175. 
Murakami, M., Kudo, I., and Inoue, K. (1991). Eicosanoid generation 
from antigen-primed mast cells by extracellular mammalian 14-kDa 
group II phospholipase A2. FEBS Lett. 294, 247-251. 
Murakami, M., Kudo, I., Suwa, Y., and Inoue, K. (1992). Release of 
14-kDa group-II phospholipase A2 from activated mast cells and its 
possible involvement in the regulation of the degranulation process. 
Eur. J. Biochem. 209, 257-265. 
Murakami, M., Kudo, I., and Inoue, K. (1993). Molecular nature of 
phospholipases A2 involved in prostaglandin 12 synthesis in human 
umbilical vein endothelial cells. Possible participation of cytosolic and 
extracellular type II phospholipases A~. J. Biol. Chem. 268, 839-844. 
Niculescu, F., Rus, H., Shin, S., Lang, T., and Shin, M. L. (1993). 
Generation of diacylglycerol and ceramide during homologous com- 
plement activation. J. Immunol. 150, 214-224. 
Pernas, P., Masliah, J., Olivier, J. L., Salvat, C., Rybkine, T., and 
B~r~ziat, G. (1991). Type il phospholipase A2 recombinant overexpres- 
sion enhances stimulated arachidonic acid release. Biochem. Bio- 
phys. Res. Commun. 178, 1298-1305. 
Pfeilschifter, J., Schalwijk, C., Briner, V. A., and van den Bosch, H. 
(1994). Cytokine-stimulated secretion of group II phospholipase A2 by 
rat mesangial cells: its contribution to arachidonic acid release and 
prostaglandin synthesis by cultured rat glomerular cells. J. Clin. Invest. 
92, 2516-2523. 
Radvanyi, F., Jordan, L., Russo-Marie, F., and Bon, C. (1989). A sensi- 
tive and continuous assay for phospholipase A2 using pyrene-labeled 
phospholipids in the presence of serum albumin. Anal. Biochem. 177, 
103-109. 
Ransac, S., Aarsman, A. J., van den Bosch, H., Gancet, C., de Haas, 
G. H., and Verger, R. (1992). Rat platelet phospholipase A2: kinetic 
characterization using the monomolecular film technique. Eur. J. Bio- 
chem. 204, 793-797. 
Raval, P. J., and Allan, D. (1984). Phospholipid asymmetry in the mem- 
branes of intact human erythrocytes and in spectrin-free microvesicles 
derived from them. Biochim. Biophys. Acta 772, 192-196. 
Riendeau, D., Guay, J., Weech, P. K., Lalibert~, F., Yergey, J., Li, C., 
Desmarais, S., Perrier, H., Liu, S., NicolI-Griffith, D., and Street, I. P. 
(1994). Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa 
phospholipase A2, blocks production of arachidonate and 12-hydroxy- 
eicosatetraenoic acid by calcium ionophore-challenged platelets, J. 
Biol. Chem. 269, 15619-15624. 
Rugani, N., Dezan, C., de la Fourniere, L., Cozzone, P., Bellon, B., 
and Sarda, L. (1992). Separation and characterization of the precursor 
and activated forms of porcine and human pancreatic colipase by 
reversed-phase liquid chromatography. J. Chromatogr. 583,246-253. 
Schroit, A. J., and Zwaal, R. F. A. (1991). Transbilayer movement of 
phospholipids in red cell and platelet membranes. Biochim. Biophys. 
Acta 1071, 313-329. 
Schutze, S., Berkovi, D., Tomsing, O., Unger, C., and KrSnke, M. 
(1991). Tumor necrosis factor induces rapid production of 1,2,diacyl- 
glycerol by a phosphatidylcholine-specific phospholipase C. J. Exp. 
Med. 174, 975-988. 
Schwartz, R. S., Tanaka, Y., Fidler, I. J., Chui, D.-T. Y., Lubin, B., 
and Schroit, A. J. (1985). Increased adherence of sickled and phospha- 
tidylserine-enriched human erythrocytes to cultured human peripheral 
blood monocytes. J. Clin. Invest. 75, 1965-1972. 
Scott, S., Pendlebury, S. A., and Green, C. (1984). Lipid organization 
in erythrocyte membrane microvesicles. Biochem. J. 224, 285-290. 
Seilhammer, J. J., Pruzanski, W., Vadas, P., Plant, S., Miller, J. A., 
Kloss, J., and Johnson, L. K. (1989). Cloning and recombinant expres- 
sion of phospholipase A2 present in rheumatoid arthritic synovial fluid. 
J. Biol. Chem. 264, 5335-5338. 
Shukla, S. D., Coleman, R., Finean, J. B., and Michell, R. H. (1978). 
The use of phospholipase C to detect structural changes in the mem- 
branes of human erythrocytes aged by storage. Biochim. Biophys. 
Acta 512, 341-349. 
Simon, M. F., Chap, H., and Douste-Blazy, L. (1982). Human platelet 
aggregation induced by 1-alkyl-lysophosphatidic acid and its analogs: 
a new group of phospholipid mediators? Biochem. Biophys. Res. Com- 
mun. 108, 1743-1750. 
Stein, J. M., and Luzio, J. P. (1991). Ectocytosis caused by sublytic 
autologous complement attack on human neutrophils: the sorting of 
endogenous plasma-membrane proteins and lipids into shed vesicles. 
Biochem. J. 274, 381-386. 
Sugiura, T., Tokumura, A., Gregory, L., Nouchi, T., Weintraub, S. T., 
and Hanahan, D. J. (1994). Biochemical characterization of the interac- 
tion of lipid phosphoric acids with human platelets: comparison with 
platelet activating factor. Arch. Biochem. Biophys. 311,358-368. 
Thannhauser, T. W., and Scheraga, H. A. (1985). Reversible blocking 
of half-cystine residues of proteins and an irreversible specific deami- 
dation of asparagine-67 of S-sulforibonuclease under mild conditions. 
Biochemistry 24, 7681-7688. 
Vadas, P., Browning, J., Edelson, J., and Pruzanski, W. (1993). Extra- 
cellular phospholipase A2 expression and inflammation: the relation- 
ship with associated disease states. J. Lipid Mediators 8, 1-30. 
van den Bosch, H. (1980). Intracellular phospholipases A. Biochim. 
Biophys. Acta 604, 191-246. 
Verkleij, A. J., Zwaal, R. F. A., Roelofsen, B., Comfurius, P., Kastelijn, 
D., and van Deenen, L. L. M (1973). Asymmetric distribution of phos- 
pholipids in the human red cell membrane: combined study using 
phospholipases and freeze-etch electron microscopy. Biochim. Bio- 
phys. Acta 323, 178-193. 
Wright, G. W., Ooi, C. E., Weiss, J., and Elsbach, P. (1990). Purification 
of a cellular (granulocyte) and an extracellular (serum) phospholipase 
A2 that participates in the destruction of Escherichia coil in a rabbit 
inflammatory exudate. J. Biol. Chem. 265, 6675-6681. 
Zachowski, A. (1993). Phospholipids in animal eukaryotic membranes: 
transverse asymmetry and movement. Biochem. J. 294, 1-14. 
Zwaal, R. F. A., Roelofsen, B., Comfurius, P., and van Deenen, L. L.M. 
(1975). Organization of phospholipids in human red cell membranes as 
detected by the action of various purified phospholipases. Biochim. 
Biophys. Acta 406, 83-96. 
Zwaal, R. F. A., Comfurius, P., and Bevers, E. M. (1992). Platelet 
procoagulant activity and microvesicle formation: its putative role in 
hemostasis and thrombosis. Biochim. Biophys. Acta 1180, 1-8. 
